UNSPSC 51401906: Rilmazafone hydrochloride

This classification denotes a sedative and hypnotic with the molecular structure C21H20CL2N6O3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 25T258X8BV chemically known as 5-(((2-aminoacetyl)amino)methyl)-1-(4-chloro-2-(2-chlorobenzoyl)phenyl)-n,n-dimethyl-1h-1,2,4-triazole-3-carboxamide hydrochloride, but more commonly known as rilmazafone hydrochloride, which bears US NIH Compound Identifier 135366.

European Medicines Agency schedules Rilmazafone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22078. Most nations, for tariff and trade purposes, schedule rilmazafone hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, RILMAZAFONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)C(=O)C1NC(N(N1)C2CCC(CC2C(=O)C3CCCCC3CL)CL)CNC(=O)CN.CL.

UNSPSC 51401906 Rilmazafone hydrochloride is a Commodity code, but the recent state and local contract opportunities tagged under it do not reflect procurement of rilmazafone specifically. Instead, the opportunities show purchasing of naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs—a mismatch that signals the code shows little relevant recent activity for rilmazafone itself. The issuing bodies pursuing pharmaceutical procurement under this coding are diverse: Seminole County, Florida (a county health authority); the Texas Health and Human Services Commission (a state agency); and the Minnesota Multistate Cooperative Purchasing Alliance (a cooperative purchasing vehicle administered by the Minnesota Department of Administration). The concrete work being solicited includes procurement of naloxone and drug deactivation systems for community health, generic pharmaceutical products through authorized wholesalers, and exploratory market intelligence on direct-to-manufacturer prescription programs.

Geographic activity centers on Florida, Texas, and Minnesota, with the Minnesota cooperative covering participating jurisdictions including Oregon. Representative recent opportunities include Seminole County's IFB60459723LAS seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the Texas HHS Commission's RFI No. HHS0017013 (posted April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription fulfillment; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (due March 26, 2026) establishing multiple contracts for generic pharmaceuticals and OTC products through authorized wholesalers with awards effective July 1, 2026. The rilmazafone code itself does not align with the scope of recent solicitations, suggesting limited current demand or a coding classification misalignment in state and local procurement systems.